US · Healthcare · Drug Manufacturers - General
EPS came in at 2.55 against a street estimate of 2.17 — a beat of 17.5%.
Analysts rate Gilead Sciences Inc a buy (22 buy, 5 hold, 1 sell out of 28) with an average price target of $172.50.
CONFIDENT Gilead reported strong third-quarter growth led by HIV, Trodelvy and Livdelzi, raised 2026 guidance, and advanced multiple launch opportunities while flagging future Biktarvy pricing pressure. Q3 FY26 Management highlighted U.S. and European demand growth for Livdelzi and Trodelvy; no consolidated regional revenue split was discussed. Analysts focused on IRA pricing, HIV franchise durability, weekly oral PrEP, pipeline catalysts, margins and cell-therapy safety. Management emphasized diversification, continued launch execution and disciplined spending while acknowledging future Biktarvy pressure. 2026-10-29…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 9.82% |
| Vanguard Capital Management, LLC | 6.54% |
| FMR Inc | 5.39% |
| State Street Corp | 4.94% |
| Capital World Investors | 3.30% |
| Amvescap Plc. | 3.21% |
| Vanguard Portfolio Management, LLC | 2.85% |
| Geode Capital Management, LLC | 2.42% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Third-quarter 2026 revenue was $8,300 million, up from $7,769 million in the third quarter of 2025. • Third-quarter net income wa | 2026-10-30 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Q3 2026 total product sales increased 13% year over year to $8.3 billion. • Product sales excluding Veklury increased 16% to $8. | 2026-10-29 |
| Quarterly report · Q2 2026 GILEAD SCIENCES, INC. – Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Total revenues (6M 2026): $14,763 million vs. $13,749 million (6M 2025), +7.4% incre | 2026-08-06 |
| Results announced · Q3 2026 GILEAD SCIENCES Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Q2 2026 Total Revenues: $7.8 billion, up 10% year-over-year • Q2 2026 Product Sales: $7. | 2026-08-04 |
| Material agreement · Q2 2026 GILEAD SCIENCES, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Company issued $3,000,000,000 in new senior notes across four tranches on May 20, 2026 • | 2026-05-20 |
| Quarterly report · Q1 2026 GILEAD SCIENCES, INC. – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Total revenues Q1 2026: $6,960 million (Q1 2025: $6,667 million) – up 4.4% • Product | 2026-05-07 |
| Results announced · Q2 2026 GILEAD SCIENCES Q1 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Total Q1 2026 revenues: $7.0 billion, up 4% year-over-year • Product sales: $6.9 billion | 2026-05-07 |
| Shareholder vote results · Q2 2026 GILEAD SCIENCES, INC. – 2026 ANNUAL MEETING SUMMARY HEADLINE NUMBERS • Annual meeting held April 30, 2026 • Total shares entitled to vote: 1,241,222 | 2026-05-04 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | $0.82 / share ex-date Dec 15, 2026 · pay Dec 30, 2026 | 2026-12-15 |
| Dividend | $0.82 / share ex-date Sep 15, 2026 · pay Sep 29, 2026 | 2026-09-15 |
| Dividend | $0.82 / share ex-date Jun 15, 2026 · pay Jun 29, 2026 | 2026-06-15 |
| Dividend | $0.82 / share ex-date Mar 13, 2026 · pay Mar 30, 2026 | 2026-03-13 |
| Dividend | $0.79 / share ex-date Dec 15, 2025 · pay Dec 30, 2025 | 2025-12-15 |
| Announcement | Date |
|---|---|
| Completed acquisition of Arcellx, Inc. for $115 per share plus CVR Gilead Sciences completed its acquisition of Arcellx on April 28, 2026, for approximately $7.1 billion. Shareholders received $115 per share in cash plus one contingent value right (CVR) wor | 2026-04-28 |
| Gilead to acquire Arcellx for $115 per share plus contingent payments Gilead Sciences agreed to acquire Arcellx, Inc. for $115 per share in cash plus one contingent value right (CVR) worth up to $5 per share upon achieving a specified milestone. The total deal | 2026-02-23 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Gilead Sciences Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.